Literature DB >> 24250289

Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

X G Guan1, X Q Guan, K Feng, R Jian, D Tian, D Tian, H B Tong, X Sun.   

Abstract

BACKGROUND: Angiocidin plays a key role in angiogenesis and tumor progression. High angiocidin expression is detected in some kind of solid tumors and tumor vascular endothelial cells. Several reports have shown the inhibition of angiogenesis and tumor growth caused by angiocidin. However, the role of angiocidin in liver cancers growth is still unclear.
OBJECTIVES: To examine angiocidin expression in SMMC-7221 and HepG2 cells and the role of angiocidin in liver cancer cell growth.
METHODS: RT-PCR and western blot are used in this study to detect angiocidin expression. SiRNA and MTT experiments are used in exploring the role of angiocidin in tumor cell growth.
RESULTS: Our study showed high angiocidin expression in two kinds of liver cancer cells. Angiocidin protein production in HepG2 cells were reduced significantly by siRNA. When HepG2 cells were transfected with siRNA-angiocidin, these cells showed very low proliferation activity compared with control cells. Our study suggests that reduction of angiocidin may contribute to decreased proliferation activity in liver cancer cells.
CONCLUSION: Angiocidin is highly expressed in liver cancer cells, and it may play a key role in tumor growth of liver cancers.

Entities:  

Keywords:  angiocidin; cell proliferation; siRNA

Mesh:

Substances:

Year:  2013        PMID: 24250289      PMCID: PMC3824429          DOI: 10.4314/ahs.v13i3.5

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  14 in total

1.  Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.

Authors:  J J Roth; D M Reiver; M S Granick; V L Rothman; R F Nicosia; G P Tuszynski
Journal:  Histol Histopathol       Date:  1997-10       Impact factor: 2.303

Review 2.  Treatment of hepatocellular carcinoma: is there an optimal strategy?

Authors:  María Varela; Margarita Sala; Josep M Llovet; Jordi Bruix
Journal:  Cancer Treat Rev       Date:  2003-04       Impact factor: 12.111

Review 3.  Signaling pathways in hepatocellular carcinoma.

Authors:  Daniela Sia; Augusto Villanueva
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

4.  Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Authors:  Yamini Sabherwal; Vicki L Rothman; Ronnie T P Poon; George P Tuszynski
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

5.  Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein.

Authors:  Yamini Sabherwal; Vicki L Rothman; Svetoslav Dimitrov; Darryl Z L'Heureux; Cezary Marcinkiewicz; Mahesh Sharma; George P Tuszynski
Journal:  Exp Cell Res       Date:  2006-04-30       Impact factor: 3.905

6.  Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model.

Authors:  Catherine Liebig; Neeti Agarwal; Gustavo E Ayala; Gordana Verstovsek; George P Tuszynski; Daniel Albo
Journal:  J Surg Res       Date:  2007-08-23       Impact factor: 2.192

7.  The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

Authors:  A Gaurnier-Hausser; G P Tuszynski
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

Authors:  Jing Zhou; Vicki L Rothman; Irene Sargiannidou; Svetoslav Dimitrov; Cuie Qiu; Elana Smith; Joel Sheffield; Mahesh Sharma; George P Tuszynski
Journal:  J Cell Biochem       Date:  2004-05-01       Impact factor: 4.429

9.  Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.

Authors:  G P Tuszynski; R F Nicosia
Journal:  Lab Invest       Date:  1994-02       Impact factor: 5.662

10.  Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.

Authors:  G P Tuszynski; V L Rothman; M Papale; B K Hamilton; J Eyal
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  1 in total

1.  Non-communicable diseases are reaching epidemic proportions: evidence from low and middle income countries.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.